Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Decreasing Function

Decreasing Function

A decreasing function describes a relationship where the output consistently declines as the input increases. This means that for any two input values, if one is greater than the other, the corresponding output is smaller. Mathematically, a function f is decreasing on an interval I if for every x1 < x2 in I, f (x1) > f (x2). This type of behavior is visually identified on a graph that slopes downward from left to right.The nature of a function can be analyzed by calculating...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Decreased Body Temperature

Decreased Body Temperature

A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...

Decreased pulse rate

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Hepatic Portal System

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Publisher Correction: Spatial transcriptomics uncovers vasculature-centered cellular interactions driving Japanese encephalitis progression in a mouse model.

Nature communications·2026

Same author

Assessment of reliability and validity of specific agility test indicators for amateur boxing.

PeerJ·2026

Same author

Thermoreversible Diels-Alder Crosslinked Networks in Recycled Poly(ethylene terephthalate) for Reprocessability and Self-Healing.

Polymers·2026

Same author

The effects of stroboscopic vision training on sports vision ability performance and punching performance in female boxers.

Frontiers in physiology·2026

Same author

Machine learning model for predicting rebleeding risk after endoscopic variceal ligation in esophageal variceal bleeding.

Scientific reports·2026

Same author

PARG Governs a PARylation-Ubiquitination Toggle that Stabilizes RAD51AP1 to Drive Homologous Recombination-Mediated Chemoresistance.

Cancer research·2026

Search research articles

Related Experiment Video

Updated: Feb 8, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection.

Min Zhang¹, Dexin Wang², Haidong Liu¹

¹Department of Gastroenterology, Qingdao NO.6 People's Hospital, Qingdao, Shandong 266033 People's Republic of China.

Infectious Agents and Cancer

|July 7, 2018

Summary

This summary is machine-generated.

Tenofovir disoproxil fumarate (TDF) offers better disease-free survival for chronic hepatitis B patients with liver cirrhosis compared to entecavir (ETV). TDF treatment duration is linked to a reduced risk of developing liver cancer.

Keywords:

Chronic hepatits B Entecavir Hepatocellular carcinoma Nucleus(t)ide analogues Tenofovir

More Related Videos

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Related Experiment Videos

Last Updated: Feb 8, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

Area of Science:

Hepatology
Virology
Oncology

Background:

Chronic hepatitis B (CHB) is a leading cause of liver cirrhosis and hepatocellular carcinoma (HCC).
Tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are standard first-line antiviral therapies for CHB.
The comparative prognostic impact of TDF versus ETV on CHB-related HCC is not well-established.

Purpose of the Study:

To compare the prognosis of CHB-related liver cirrhosis patients treated with TDF versus ETV.
To evaluate the impact of TDF and ETV on disease-free survival (DFS) and overall survival (OS).
To identify factors influencing HCC development in CHB patients receiving antiviral therapy.

Main Methods:

A retrospective study of 233 CHB-related compensated cirrhosis patients treated with TDF or ETV monotherapy.
Comparison of baseline characteristics including Child-Pugh score, liver enzymes, bilirubin, HBeAg status, and HBV DNA levels.
Analysis of DFS and OS using survival analysis, with multivariable analysis to assess predictors of HCC development.

Main Results:

Patients receiving TDF (n=107) showed significantly longer DFS compared to those on ETV (n=126) (p < 0.05).
Multivariable analysis revealed that TDF treatment duration was significantly associated with a lower probability of HCC development (HR, 0.35; 95% CI, 0.33-0.84; p < 0.05).
No significant differences in baseline characteristics were observed between the TDF and ETV groups.

Conclusions:

Antiviral therapy with tenofovir disoproxil fumarate (TDF) is associated with improved prognosis in CHB-related liver cirrhosis patients.
TDF monotherapy may offer superior disease-free survival and reduced HCC risk compared to entecavir (ETV).
Further prospective studies are warranted to confirm these findings and elucidate the mechanisms underlying TDF's benefits.